Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Research progress of mesenchymal stem cells/stromal cells and their derivatives against cell senescence in the treatment of osteoarthritis

Deng D., Wu Y., Wu T., Huang D., Liang X., Tan C.

Clinical Trial on Osteoarthritis, Chronic Inflammation, published in Ann Med (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Ann Med (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41919394
PMCID
PMC13045180
DOI
10.1080/07853890.2026.2627667

Abstract (original English)

Background Cellular senescence plays a critical role in the pathogenesis and progression of osteoarthritis (OA), contributing to articular cartilage degradation, chronic inflammation, and joint function impairment. Mesenchymal stem cells/stromal cells (MSCs) and their derivatives have emerged as potential targets for novel therapeutic strategies against cell senescence in OA, as they exert anti-aging effects in repairing damaged cartilage through multiple mechanisms-including regulating age-related signaling pathways, reducing the secretion of pro-inflammatory cytokines, and improving mitochondrial function. Discussion In recent years, a growing body of in-depth studies has focused on various types of MSCsand their derivatives, revealing subtle differences in their anti-cell senescence pathways and therapeutic effects. This review summarizes the latest cutting-edge research, systematically exploring the multi-dimensional roles of these MSCs and their derivatives in ameliorating senescent cell-related pathology in OA, and highlighting their potential clinical application value. Conclusions Despite the promising anti-aging effects of MSCs and their derivatives in OA treatment, further molecular-level mechanistic studies and large-scale clinical trials are required to verify the efficacy and safety of therapies based on their anti-cell senescence properties. These efforts are expe

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Cartilage, ArticularMesenchymal Stem CellsAnimalsHumansOsteoarthritisMesenchymal Stem Cell TransplantationSignal TransductionCellular Senescence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research